AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34097368 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 135
Study 34097368 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil
Number of subjects: 135
Study 32096120 — intervention group
Group type: COMPARATOR
Intervention: Mild illness
Number of subjects: 471
Study 32096120 — intervention group
Group type: COMPARATOR
Intervention: Maximal (100%) burst suppression burden
Number of subjects: 471
Study 32096120 — intervention group
Group type: COMPARATOR
Intervention: High cumulative propofol dose (1316 mg/kg)
Number of subjects: 471
Study 32096120 — intervention group
Group type: COMPARATOR
Intervention: Propofol exposure
Number of subjects: 471
Study 32096120 — intervention group
Group type: EXPERIMENTAL
Intervention: Burst suppression
Number of subjects: 471
Study 34340096 — intervention group
Group type: EXPERIMENTAL
Intervention: Shangliao point injection combined with epidural analgesia
Number of subjects: 93
Study 34340096 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 93
Study 34340096 — intervention group
Group type: EXPERIMENTAL
Intervention: Shangliao point injection
Number of subjects: 93
Study 34340096 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia and saline injection
Number of subjects: 93
Study 36231542 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based personalized intervention based on artificial intelligence
Number of subjects: 0
Study 36231542 — intervention group
Group type: COMPARATOR
Intervention: Standard primary health care by nurses
Number of subjects: 0
Study 33431900 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model of live birth for ART patients
Number of subjects: 0
Study 32593779 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose aspirin (150 mg/day)
Number of subjects: 0
Study 32593779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35032437 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus cabozantinib
Number of subjects: 651
Study 35032437 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 651
Study 32926259 — intervention group
Group type: EXPERIMENTAL
Intervention: Transinguinal preperitoneal repair with modified Kugel patch (MK)
Number of subjects: 200
Study 32926259 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein repair (LR)
Number of subjects: 200
Study 32641101 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib (up to 3 cycles, each 21 days with 4 subcutaneous applications)
Number of subjects: 50
Study 32641101 — intervention group
Group type: COMPARATOR
Intervention: Placebo (up to 3 cycles, each 21 days with 4 subcutaneous applications)
Number of subjects: 50
Study 36222880 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-mg dose of amiloride
Number of subjects: 10
Study 36222880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 33716004 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 744
Study 33716004 — intervention group
Group type: COMPARATOR
Intervention: Control (no statin use)
Number of subjects: 744
Study 36282602 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol PPE
Number of subjects: 16
Study 32473592 — intervention group
Group type: EXPERIMENTAL
Intervention: Tethered swimming (TS)
Number of subjects: 14
Study 32473592 — intervention group
Group type: COMPARATOR
Intervention: Control (moderate pace swimming)
Number of subjects: 14
Study 32543054 — intervention group
Group type: EXPERIMENTAL
Intervention: EPOCH interventions targeting obesity-related behaviours; specific interventions not detailed.
Number of subjects: 0
Study 32543054 — intervention group
Group type: EXPERIMENTAL
Intervention: Delivery features of EPOCH interventions; specific details not provided.
Number of subjects: 0
Study 32543054 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour change techniques (BCTs) used in EPOCH interventions; specific techniques listed.
Number of subjects: 0
Study 32543054 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations from interview analyses; specific recommendations not detailed.
Number of subjects: 0
Study 34922807 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation Group (RG) - five days of intensive exercise program and early ambulation
Number of subjects: 40
Study 34922807 — intervention group
Group type: COMPARATOR
Intervention: Mobilization Group (MG) - five days of standard gait training and early ambulation
Number of subjects: 40
Study 33536055 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-plant cannabis extract (BOL‐DP‐O‐01‐W) containing cannabidiol and Δ9‐tetrahydrocannabinol at a 20:1 ratio
Number of subjects: 150
Study 33536055 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-plant cannabis extract (BOL‐DP‐O‐01‐W)
Number of subjects: 150
Study 33536055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 35605176 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax-rituximab (VenR)
Number of subjects: 389
Study 35605176 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax-rituximab (VenR) with undetectable minimal residual disease (uMRD) at end of treatment (EOT)
Number of subjects: 389
Study 32565468 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs assessed using the CONSORT 2010 Statement
Number of subjects: 0
Study 32565468 — intervention group
Group type: EXPERIMENTAL
Intervention: Descriptive statistics and secondary analyses
Number of subjects: 0
Study 36241511 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid administered before surgical incision (pre-induction groups)
Number of subjects: 212
Study 36241511 — intervention group
Group type: COMPARATOR
Intervention: Tranexamic acid administered just before tourniquet release (pre-release groups)
Number of subjects: 212
Study 36241511 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose groups (tranexamic acid administered once)
Number of subjects: 212
Study 36241511 — intervention group
Group type: COMPARATOR
Intervention: Double-dose groups (tranexamic acid administered twice)
Number of subjects: 212
Study 36241511 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose groups
Number of subjects: 212
Study 36241511 — intervention group
Group type: COMPARATOR
Intervention: Double-dose groups
Number of subjects: 212
Study 34878081 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic paste (CTZ)
Number of subjects: 52
Study 34878081 — intervention group
Group type: COMPARATOR
Intervention: Iodoform paste (GP)
Number of subjects: 52
Study 33991032 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxytherapy (intradermal injection of 5 cc carbon-dioxide gas once weekly for 6 weeks)
Number of subjects: 21
Study 33991032 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) therapy (intradermal injection of PRP every 2 weeks for three times)
Number of subjects: 21
Study 33991032 — intervention group
Group type: COMPARATOR
Intervention: Comparison of carboxytherapy and PRP
Number of subjects: 21
Study 35183487 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Indicator Behaviour Scale
Number of subjects: 80
Study 35183487 — intervention group
Group type: COMPARATOR
Intervention: Verbal Numerical Scale or Visual Analogue Scale
Number of subjects: 80
Study 33709907 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg daily
Number of subjects: 200
Study 33709907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 33061349 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 25 mcg BID
Number of subjects: 0
Study 33061349 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 50 mcg BID
Number of subjects: 0
Study 33061349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 616083574 — intervention group
Group type: COMPARATOR
Intervention: Paper based manual training
Number of subjects: 19
Study 616083574 — intervention group
Group type: EXPERIMENTAL
Intervention: EyeSi simulator training
Number of subjects: 19
Study 32584415 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) treatment
Number of subjects: 672
Study 32466879 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavacamten (200 ng/ml)
Number of subjects: 59
Study 32466879 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavacamten (500 ng/ml)
Number of subjects: 59
Study 32466879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 35584934 — intervention group
Group type: EXPERIMENTAL
Intervention: Alumina-ceria polishing paste with different ratios of deionized water:alumina:ceria (AC0.5, AC1, AC1.5, AC2, AC2.5, AC3)
Number of subjects: 70
Study 35584934 — intervention group
Group type: COMPARATOR
Intervention: Diamond paste (Control group)
Number of subjects: 70
Study 32920767 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 Gy equivalent dose
Number of subjects: 200
Study 32920767 — intervention group
Group type: COMPARATOR
Intervention: 50 Gy equivalent dose
Number of subjects: 200
Study 32629757 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (6000 IU daily for eight weeks)
Number of subjects: 28
Study 32629757 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 28
Study 35093047 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided internet- and mobile-based cognitive behavioral therapy (iCBT) youthCOACHCD (IG, n=15)
Number of subjects: 30
Study 35093047 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (CG, n=15) receiving unguided version of iCBT six months post-randomization
Number of subjects: 30
Study 35093047 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided internet- and mobile-based cognitive behavioral therapy (iCBT) youthCOACHCD (IG)
Number of subjects: 30
Study 33063528 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate and vigorous physical activities (MVPA) among Met/Met carriers
Number of subjects: 3040
Study 33063528 — intervention group
Group type: COMPARATOR
Intervention: Moderate and vigorous physical activities (MVPA) among Val/Val and Val/Met carriers
Number of subjects: 3040
Study 35597965 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation program combining multimodal exercises with psychologist-led cognitive-behavioral therapy sessions
Number of subjects: 170
Study 35597965 — intervention group
Group type: COMPARATOR
Intervention: General care physiotherapy
Number of subjects: 170
Study 34812096 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedle fractional radiofrequency (MFR)
Number of subjects: 15
Study 34812096 — intervention group
Group type: COMPARATOR
Intervention: Fractional erbium-doped glass 1,565-nm laser (NAFL)
Number of subjects: 15
Study 34812096 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (MFR and NAFL)
Number of subjects: 15
Study 35488479 — intervention group
Group type: EXPERIMENTAL
Intervention: Flapless endoscope-assisted osteotome sinus floor elevation with platelet-rich fibrin (PRF)
Number of subjects: 40
Study 35488479 — intervention group
Group type: COMPARATOR
Intervention: Lateral sinus floor elevation (LSFE) using deproteinised bovine bone matrix
Number of subjects: 40
Study 33607008 — intervention group
Group type: EXPERIMENTAL
Intervention: lumacaftor–ivacaftor therapy
Number of subjects: 0
Study 32524940 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal depression (measured by Patient Health Questionnaire‐9)
Number of subjects: 3984
Study 32524940 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal and paternal depression (measured by Patient Health Questionnaire‐9)
Number of subjects: 3984
Study 32524940 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's dietary diversity
Number of subjects: 3984
Study 32524940 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's anthropometric status
Number of subjects: 3984
Study 32524940 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate or severe depression screening
Number of subjects: 3984
Study 36448651 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Aid plus Victorian Assisted Reproductive Technology Authority website
Number of subjects: 0
Study 36448651 — intervention group
Group type: COMPARATOR
Intervention: Victorian Assisted Reproductive Technology Authority website only
Number of subjects: 0
Study 35802168 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 5
Study 35802168 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 5
Study 35802168 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 5
Study 35802168 — intervention group
Group type: COMPARATOR
Intervention: Canagliflozin vs Placebo
Number of subjects: 5
Study 34878076 — intervention group
Group type: EXPERIMENTAL
Intervention: TiF4 (2.45% F‐)
Number of subjects: 60
Study 34878076 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF (2.26% F‐)
Number of subjects: 60
Study 34878076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 34878076 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study 33705500 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 129883
Study 32779195 — intervention group
Group type: EXPERIMENTAL
Intervention: Early antiretroviral therapy (ART)
Number of subjects: 133
Study 35867285 — intervention group
Group type: EXPERIMENTAL
Intervention: 980-nm diode laser
Number of subjects: 15
Study 35867285 — intervention group
Group type: COMPARATOR
Intervention: Conventional flap surgery
Number of subjects: 15
Study 33398520 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 143
Study 33398520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 32796869 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Neuro-Fuzzy Inference System (ANFIS) method
Number of subjects: 0
Study 32796869 — intervention group
Group type: EXPERIMENTAL
Intervention: ANFIS method
Number of subjects: 0
Study 36136236 — intervention group
Group type: EXPERIMENTAL
Intervention: RET
Number of subjects: 28
Study 36136236 — intervention group
Group type: EXPERIMENTAL
Intervention: RET-FO
Number of subjects: 28
Study 36136236 — intervention group
Group type: COMPARATOR
Intervention: CON
Number of subjects: 28
Study 32772069 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 117
Study 35230676 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS + PT
Number of subjects: 25
Study 35230676 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS + PT
Number of subjects: 25
Study 34761730 — intervention group
Group type: EXPERIMENTAL
Intervention: Muse (game-based meditation intervention)
Number of subjects: 77
Study 34761730 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 77
Study 35436611 — intervention group
Group type: EXPERIMENTAL
Intervention: SpikoGen® vaccine (25 μg, two doses, 3 weeks apart)
Number of subjects: 400
Study 35436611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 33990433 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured intervention programme including a 1 day education session and an individual written exercise plan over 4 months.
Number of subjects: 163
Study 33990433 — intervention group
Group type: COMPARATOR
Intervention: Control group continued with their usual level of care.
Number of subjects: 163
Study 32978182 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror Therapy (MT) combined with task-oriented training
Number of subjects: 154
Study 32978182 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapeutic Exercise (CTE) combined with task-oriented training
Number of subjects: 154
Study 32978182 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional interventions)
Number of subjects: 154
Study 35570288 — intervention group
Group type: EXPERIMENTAL
Intervention: Menstrual migraine patients
Number of subjects: 109
Study 35570288 — intervention group
Group type: COMPARATOR
Intervention: Non-menstrual migraine patients
Number of subjects: 109
Study 33794005 — intervention group
Group type: EXPERIMENTAL
Intervention: Football Fitness (FFG)
Number of subjects: 68
Study 33794005 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 68
Study 36252934 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg lutein + 2 mg zeaxanthin
Number of subjects: 288
Study 36252934 — intervention group
Group type: COMPARATOR
Intervention: Waitlist placebo
Number of subjects: 288
Study 32363968 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine infusion of 0.5 ml of platelet-rich plasma (PRP) 48 hours before embryo transfer
Number of subjects: 98
Study 32363968 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol (Control)
Number of subjects: 98
Study 32938470 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) starting from 5 mg per week for the first 2 weeks, increasing to 10 mg per week for the second 2 weeks, and 15 mg per week for the remaining period if tolerated
Number of subjects: 200
Study 32938470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 34614204 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg ramosetron with IV-PCA
Number of subjects: 88
Study 34614204 — intervention group
Group type: COMPARATOR
Intervention: 10 mg dexamethasone before induction of anesthesia with IV-PCA
Number of subjects: 88
Study 34753844 — intervention group
Group type: EXPERIMENTAL
Intervention: Licorice mouthwash
Number of subjects: 52
Study 34753844 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine mouthwash
Number of subjects: 52
Study 32925205 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescent guided surgery with 5-aminolevulinic acid
Number of subjects: 0
Study 32925205 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor-treating fields therapy
Number of subjects: 0
Study 32925205 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 0
Study 32925205 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused ultrasound combined with microbubbles
Number of subjects: 0
Study 32925205 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound devices to disrupt the blood-brain barrier
Number of subjects: 0
Study 35417339 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity (HI) variant of the programme
Number of subjects: 695
Study 35417339 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity (LI) variant of the programme
Number of subjects: 695
Study 32112583 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative group (13 participants)
Number of subjects: 49
Study 32112583 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoperative group (28 participants)
Number of subjects: 49
Study 32112583 — intervention group
Group type: COMPARATOR
Intervention: Control group (8 participants)
Number of subjects: 49
Study 35047630 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin combined with Xingnaojing injection
Number of subjects: 100
Study 35047630 — intervention group
Group type: COMPARATOR
Intervention: Ulinastatin only
Number of subjects: 100
Study 33059762 — intervention group
Group type: EXPERIMENTAL
Intervention: EACH-B intervention
Number of subjects: 2300
Study 33059762 — intervention group
Group type: COMPARATOR
Intervention: Control (normal schooling)
Number of subjects: 2300
Study 36202884 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus fermentum CECT5716 during needle aspiration
Number of subjects: 101
Study 36202884 — intervention group
Group type: COMPARATOR
Intervention: Control group (no probiotics)
Number of subjects: 101
Study 33707597 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanqi seedlings cultivated in plots with varying soil parameters
Number of subjects: 7
Study 33707597 — intervention group
Group type: EXPERIMENTAL
Intervention: Soil pH
Number of subjects: 7
Study 32816561 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol I-370
Number of subjects: 65
Study 32816561 — intervention group
Group type: COMPARATOR
Intervention: Ioversol I-320
Number of subjects: 65
Study 35851370 — intervention group
Group type: EXPERIMENTAL
Intervention: Desarda repair
Number of subjects: 100
Study 35851370 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein repair
Number of subjects: 100
Study 33156402 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (IN-OT)
Number of subjects: 0
Study 35107599 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibetan yoga program (TYP)
Number of subjects: 227
Study 35107599 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching program (STP)
Number of subjects: 227
Study 35107599 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 227
Study 34626958 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 11
Study 34014451 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurtured in Nature intervention (4-week intervention with Nature Coach, digital nudges, personalized goal feedback)
Number of subjects: 36
Study 34014451 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurtured in Nature intervention (among women who completed the intervention)
Number of subjects: 36
Study 34014451 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 34290069 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipex
Number of subjects: 60
Study 34290069 — intervention group
Group type: COMPARATOR
Intervention: Metapex
Number of subjects: 60
Study 32499263 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial ultrasound examinations of the heart and lungs together with standard care
Number of subjects: 206
Study 32499263 — intervention group
Group type: COMPARATOR
Intervention: Standard monitoring alone
Number of subjects: 206
Study 36409064 — intervention group
Group type: EXPERIMENTAL
Intervention: CTN-1 V human rabies vaccine (Vero cells) administered via the Essen Regimen (single dose on days 0, 3, 7, 14, and 28)
Number of subjects: 594
Study 36409064 — intervention group
Group type: EXPERIMENTAL
Intervention: CTN-1 V human rabies vaccine (Vero cells)
Number of subjects: 594
Study 33586072 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional chemoradiation therapy after induction chemotherapy
Number of subjects: 0
Study 33586072 — intervention group
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation
Number of subjects: 0
Study 33586072 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinations of local ablation and immunotherapy
Number of subjects: 0